BARDA tapped a team of Fred Hutch Cancer Center biostatisticians to determine the biomarkers that will serve as predictors of protective responses in next-generation COVID-19 vaccines, as well as the effectiveness of nimble new trial designs. The $17 million award will support analysis of immune responses to an oral pill and nasal spray, as well as two different decentralized trials.
John Mascarenhas, MD, discusses navtemadlin’s mechanism of action and its potential to shift the myelofibrosis treatment landscape
Nature Cancer – Swanton and colleagues present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of…
Michael T. Tees, MD, MPH, describes how BTK degraders represent a promising class of agents, highlighting the agent AC676 that is currently under evaluation.
Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.
Jenna Canzoniero, MD, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, explores the critical role of molecular tumor boards (MTB) in guiding oncologists through complex…
Esther Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, comments on a national survey conducted in Italy that investigated clinicians’ knowledge and…
On Jan. 7, a bit after 6 p.m., Ravi Salgia was at his Eaton Canyon home, at the edge of Angeles National Forest. To access…
Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
